APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer

• DOI: 10.18632/oncotarget.24357
• Publication Date: 2018-01-31T11:57:54Z
• Authors: Caroline K. Søgaard; Siver A. Moestue; Morten B. Rye; Jana Kim; Anala Nepal; Nina-Beate Liabakk; Siri Bachke; Tone F. Bathen; Marit Otterlei; Deborah K. Hill
• Keywords: Norwegian

// Caroline K. Søgaard 1, 7 , Siver A. Moestue 2, 3, 4 Morten B. Rye Jana Kim 5 Anala Nepal 1 Nina-Beate Liabakk Siri Bachke Tone F. Bathen Marit Otterlei 6, and Deborah Hill Department of Cancer Research Molecular Medicine, Norwegian University Science Technology (NTNU), Trondheim, Norway 2 Circulation Medical Imaging, 3 Laboratory Women's Children's Health, Pharmacy, Faculty Health Sciences, Nord University, Namsos, Radiology, St. Olavs Hospital, Trondheim 6 APIM Therapeutics A/S, Clinic Surgery, Correspondence to: Otterlei, email: [e-mail] Hill, [e-mail] Keywords: magnetic resonance imaging; gene expression; apoptosis; MAPK; PI3K/AKT Received: June 07, 2017 Accepted: November 06, Published: January 27, 2018 ABSTRACT Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory prostate cancer, however, it only marginally improves survival rate. The purpose present study was to examine if a peptide targeting cellular scaffold protein PCNA could improve docetaxel's efficacy. We found that docetaxel given in combination with cell penetrating containing AlkB homolog interacting motif (APIM-peptide), reduced volume limited cancer regrowth vivo immunocompetent transgenic adenocarcinoma model (TRAMP). In accordance this, we APIM-peptide enhanced efficacy vitro . Gene expression analysis on lines indicated alters genes involved signaling, apoptosis, development. These changes were not detected single agent treated cells. Our results suggest thereby affecting multiple pathways simultaneously has potential therapy advanced cancer.